GSK to acquire clinical-stage biopharmaceutical company Affinivax for US$ 3.3 billion
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
The final data from the trial showed sotrovimab reduces hospitalisation and risk of death by 79% in adults with mild-to-moderate Covid-19 who are at high risk of progression to severe disease
Subscribe To Our Newsletter & Stay Updated